Complying With the DSCSA
Dave DeJean provides his expert insight on lessons he’s learned from his plethora of time in the industry, along with an outlook on where the pharma supply chain stands in adhering to the Drug Supply Chain Security Act (DSCSA).
In this exclusive PC Podcast interview, Dave DeJean, Systech’s VP of global strategic accounts, dives into:
- The valuable lessons he’s learned along the way, given his three and half decades of experience at Systech
- An overview of the Drug Supply Chain Security Act (DSCSA), including its three main pillars
- How he would interpret this “Stabilization Period” that the FDA provided this past summer, and what he pharma industry do now during this period in order to avoid penalties later
- Whether or not he anticipates the FDA implementing any other sort of delays in the near future in order to help remedy these issues/challenges surrounding the enactment of DSCSA
The latest episode of The Pharmaceutical Commerce Podcast is available directly on SoundCloud.
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Multi-Indication Drug Branding in Today’s Pharmaceutical Industry
July 2nd 2025As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.
